Sanofi enters New Year with new deal, ends its vaccine joint venture
Sanofi has starts new year with big changes. In two separate statements the company announced closing a deal and ending a joint venture.
Pharmaceuticals, Biotechnology and Life Sciences
Sanofi has starts new year with big changes. In two separate statements the company announced closing a deal and ending a joint venture.
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
Shire has entered a new year with a new non-executive director, as it has appointed Ian Clark to the board. His new duties started immediately.
If you have problems with settling your stomach after having a nice meal, even if it had passed a couple of hours, you don’t want to jump to drugs immediately. Try these seven steps to reduce your abdominal pain.
Mylan has had a rather busy week, as it got approvals for three of its generic medicines in last three days. It announced launching three generics into the multi-billion U.S. worth market on Wednesday and Thursday.
In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.
Analytical company Eurofins Scientific has broadened its testing facilities in Spain, as it is about to buy a Spanish pharmaceutical company Villapharma Research SL.
Argenx (argenx) is currently working on a therapy for the treatment of acute myeloid leukemia (AML), and during the holiday season, the company has revealed how it is going.
France’s Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.
Seattle Genetics Inc said four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage studies.